A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221154
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
women of non-childbearing potential.
- Provision of informed consent prior to any study specific procedures
- Nailve T2DM patients with HbA1c 7.5% or more but 10% or less, or T2DM Patients treated with one or two oral anti-hyperglycaemic agent(s) with HbA1c 7.5% or more but 9.5% or less at enrolment visit (Visit1)
- Clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, hepatic disease and haematological disease.
- The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.
- Participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method